Lillys

People dropped out of Eli Lilly’s new GLP-1 drug trial because they lost too much weight

by
People dropped out of Eli Lilly’s new GLP-1 drug trial because they lost too much weight

Too much of a good thing? Participants taking the highest dose of Eli Lilly’s new GLP-1 drug lost an average of 28.7% of their body weight in a late-stage trial, putting it on track to be a heavyweight in the crowded world of weight-loss and diabetes treatments. But in a surprising twist, top-line results show … Read more

Lilly’s weight-loss drug reduces sleep apnea severity in late-stage trials

by
Lilly’s weight-loss drug reduces sleep apnea severity in late-stage trials

April 17 (Reuters) – Eli Lilly (LLY.N), said on Wednesday its weight-loss drug helped reduce episodes of irregular breathing associated with a common sleep-related disorder in two late-stage trials, paving the way for expanding use of the drug. The drug cut the frequency of irregular breathing episodes by as much as 63% across the two studies. … Read more